Aclaris Therapeutics Reports First Quarter 2021 Financial Results

… and planning to initiate two additional trials of ATI-450 in hidradenitis suppurativa and psoriatic arthritis.” Research and Development Highlights:.

Source link

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply

Your email address will not be published. Required fields are marked *